Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.

ABSTRACT:

Background

Prostate cancer (PC) is a multifocal disease. DNA methylation alterations are not restricted to the immediate peritumor environment, but spatially widespread in the adjacent and distant histologically normal prostate tissues. In the current study, we utilized high-throughput methylation arrays to identify epigenetic changes in the urine from men with and without cancer.

Design, setting, and participants

DNA urine samples were enriched for methylated fragments using MBD methyl-binding antibodies and applied to high density CytoScanHD arrays. Significant loci were validated using quantitative pyrosequencing and binary logistic regression modeling applied to urine sample analyses in a training (n = 83) and validation approach (n = 84). Methylation alterations in pros

SUBMITTER: Jarrard WE 

PROVIDER: S-EPMC6590820 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature